Brian brings more than 25 years of experience in drug development in the pharmaceutical and biotechnology industries, in areas including oncology, haematology and rare diseases.

Brian joined Step Pharma in 2022. He previously served for 12 years at ArQule, where he was CMO and Head of Research and Development; during this time, he led the clinical development of the BTK inhibitor ARQ 531 before the company’s $2.7 billion acquisition by Merck in 2020. His previous roles include CMO and Senior Vice President, Clinical and Regulatory Affairs, at Ziopharm, where he oversaw the development of new cancer drugs. Earlier in his career, he held leadership roles at Bayer Healthcare and Leo Laboratories. Alongside his role at Step Pharma, Brian continues to act as a consultant to other biotech companies, and also serves on the boards of Mereo BioPharma, Enlivex, Cyclacel Pharmaceuticals and Infinity Pharmaceuticals.

Brian, who practised medicine prior to his career in the biopharmaceutical industry, holds a medical degree from the University of Pretoria, South Africa, and completed a fellowship at the University of Toronto, Canada.


Step Pharma is led by a highly motivated management team and an exceptional syndicate of international investors, all driven to bring about a step change in cancer treatment for patients.